Goldman Sachs Group Inc
Change company Symbol lookup
Select an option...
GS Goldman Sachs Group Inc
ONON On Holding AG
XNCR Xencor Inc
ALT Altimmune Inc
RZLT Rezolute Inc
BNKU MicroSectors? U.S. Big Banks Index 3X Leveraged ETNs
SGFY Signify Health Inc
FRC First Republic Bank
BACK IMAC Holdings Inc
LYLT Loyalty Ventures Inc
Go

Financials : Capital Markets | Large Cap Value
Company profile

The Goldman Sachs Group, Inc. is a global financial institution that delivers a range of financial services across investment banking, securities, investment management and consumer banking to a diversified client base that includes corporations, financial institutions, governments and individuals. The Company segments include Global Banking & Markets, Asset & Wealth Management and Platform Solutions. The Global Banking & Markets segment includes financing, advisory services, risk distribution, and hedging for its institutional and corporate clients, including Fixed Income, Currency and Commodities (FICC) and Equities, Investment Banking and Marquee. The Asset & Wealth Management segment includes advice, investing, and execution for institutions and individuals across public and private markets. The Platform Solutions segment includes consumer platforms, such as partnerships offering credit cards and point-of-sale financing, and transaction banking and other platform businesses.

Price
Delayed
$318.58
Day's Change
9.05 (2.92%)
Bid
--
Ask
--
B/A Size
--
Day's High
320.32
Day's Low
315.35
Volume
(Light)

Today's volume of 1,536,553 shares is on pace to be much lighter than GS's 10-day average volume of 4,214,926 shares.

1,536,553

NEO LAWSUIT ALERT: Levi & Korsinsky Notifies NeoGenomics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

5:45 am ET January 26, 2023 (PR Newswire) Print

Levi & Korsinsky, LLP notifies investors in NeoGenomics, Inc. ("NeoGenomics" or the "Company") (NASDAQ: NEO) of a class action securities lawsuit.

https://mma.prnewswire.com/media/1687309/LK_1920x1080_Logo.jpg

CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of NeoGenomics investors who were adversely affected by alleged securities fraud between February 27, 2020 and April 26, 2022. Follow the link below to get more information and be contacted by a member of our team:

https://www.zlk.com/pslra-1/neogenomics-lawsuit-submission-form?prid=35917&wire=4

NEOinvestors may also contact Joseph E. Levi, Esq. via email atjlevi@levikorsinsky.comor by telephone at (212) 363-7500.

CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (1) defendants represented to investors that it had a "comprehensive menu" of cancer tests with "every kind of testing modality that you can use for cancer, including some of the fast-growing new ones, like next-generation sequencing," which positioned the Company as a "one-stop-shop" for pathologists and gave NeoGenomics "a competitive advantage" as a "go-to reference lab with a comprehensive menu for just about any kind of tests that you want to have done in cancer"; and (2) defendants represented that NeoGenomics could "leverage" the supposedly "fixed cost" structure of its business to improve profitability as revenue increased and touted the Company's "robust Compliance Program . . . to ensure compliance with the myriad of . . . laws, regulations and governmental guidance applicable to our business."

WHAT'S NEXT? If you suffered a loss in NeoGenomics during the relevant time frame, you have until February 6, 2023to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate.

WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States.

CONTACT:Levi & Korsinsky, LLP Joseph E. Levi, Esq.Ed Korsinsky, Esq.55 Broadway, 10th FloorNew York, NY 10006jlevi@levikorsinsky.comTel: (212) 363-7500Fax: (212) 363-7171www.zlk.com

https://c212.net/c/img/favicon.png?sn=NY97356&sd=2023-01-26

View original content to download multimedia:https://www.prnewswire.com/news-releases/neo-lawsuit-alert-levi--korsinsky-notifies-neogenomics-inc-investors-of-a-class-action-lawsuit-and-upcoming-deadline-301731185.html

SOURCE Levi & Korsinsky, LLP

https://rt.newswire.ca/rt.gif?NewsItemId=NY97356&Transmission_Id=202301260545PR_NEWS_USPR_____NY97356&DateId=20230126

comtex tracking

COMTEX_423327358/1005/2023-01-26T05:45:14

Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.